AGC1-7 Antibody

AGC1 (Aspartate-Glutamate Carrier 1) Antibodies

AGC1, encoded by the SLC25A12 gene, is a mitochondrial carrier critical for aspartate/glutamate exchange and myelination. Antibodies targeting AGC1 are essential for studying its role in neurological disorders like AGC1 deficiency syndrome.

Key Research Applications:

• Western Blotting (WB): Detects AGC1 expression in brain, muscle, and liver tissues .

• Immunoprecipitation (IP): Isolates AGC1 for functional studies, such as transport activity assays .

• Disease Models: Used to validate AGC1 knockdown in oligodendrocyte precursor cells (OPCs) and neurospheres, revealing impaired proliferation and differentiation .

Example Antibody:

Angiotensin 1-7 (Ang1-7) Antibodies

Ang1-7 is a peptide component of the renin-angiotensin system. Antibodies against Ang1-7 are used in cardiovascular and metabolic research.

Key Research Applications:

• Immunohistochemistry (IHC): Localizes Ang1-7 in kidney and vascular tissues.

• ELISA/Immunoassays: Quantifies Ang1-7 levels in plasma or tissue extracts.

• Therapeutic Studies: Evaluates Ang1-7’s role in reducing hypertension and fibrosis .

Example Antibodies:

Critical Distinctions Between AGC1 and Ang1-7 Antibodies

Research Findings Highlighting AGC1 Antibody Utility

• Myelination Defects: AGC1 knockdown in mice reduces oligodendrocyte precursor cell proliferation by 60%, linked to dysregulated PDGFα/TGFβ pathways .

• Metabolic Impact: AGC1 deficiency lowers cytosolic aspartate, impairing NAD+/NADH redox balance and cell survival under glutamine-limited conditions .

• Therapeutic Targets: AGC1 inhibition synergizes with glutaminase blockers (e.g., CB-839) to suppress tumor growth in preclinical models .

Ang1-7 Antibody Clinical Relevance

• Biomarker Potential: Elevated Ang1-7 correlates with improved outcomes in heart failure patients .

• Therapeutic Antibodies: Fc-glycan-engineered Ang1-7 antibodies show enhanced half-life in phase 1 trials for solid tumors (NCT06349408) .

Limitations and Gaps

• No peer-reviewed studies directly reference an "AGC1-7 Antibody," suggesting potential nomenclature confusion.

• Commercial Ang1-7 antibodies exhibit variability in specificity; rigorous validation is required .

Future Directions

• Develop dual-target antibodies for AGC1 and related metabolites (e.g., N-acetyl-aspartate) to address hypomyelination.

• Optimize Ang1-7 antibody-drug conjugates (ADCs) for targeted cardiovascular therapies .